Oscar Health, Inc.
Oscar Health, Inc. (OSCR) Stock Competitors & Peer Comparison
See (OSCR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| OSCR | $14.20 | -10.52% | 3.6B | 35.50 | $0.40 | N/A |
| UNH | $278.58 | -4.76% | 252.8B | 11.66 | $23.89 | +3.03% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +2.38% |
| CI | $293.93 | -3.42% | 78.5B | 16.37 | $17.94 | +1.98% |
| CVS | $58.75 | -5.01% | 74.3B | 14.02 | $4.19 | +4.50% |
| ELV | $280.43 | -5.45% | 63.1B | 11.89 | $23.58 | +2.38% |
| HUM | $229.21 | -3.34% | 27.7B | 16.17 | $14.17 | +1.54% |
| CNC | $26.76 | -9.04% | 13.3B | 3.95 | $6.78 | N/A |
| MOH | $158.22 | -16.84% | 8.6B | 7.81 | $20.28 | N/A |
| ALHC | $11.64 | -6.13% | 2.3B | -24.77 | -$0.47 | N/A |
Stock Comparison
OSCR vs UNH Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, UNH has a market cap of 252.8B. Regarding current trading prices, OSCR is priced at $14.20, while UNH trades at $278.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas UNH's P/E ratio is 11.66. In terms of profitability, OSCR's ROE is +0.11%, compared to UNH's ROE of +0.24%. Regarding short-term risk, OSCR is more volatile compared to UNH. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check UNH's competition here
OSCR vs ANTM Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, OSCR is priced at $14.20, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas ANTM's P/E ratio is 18.99. In terms of profitability, OSCR's ROE is +0.11%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, OSCR is more volatile compared to ANTM. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check ANTM's competition here
OSCR vs CI Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, CI has a market cap of 78.5B. Regarding current trading prices, OSCR is priced at $14.20, while CI trades at $293.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas CI's P/E ratio is 16.37. In terms of profitability, OSCR's ROE is +0.11%, compared to CI's ROE of +0.12%. Regarding short-term risk, OSCR is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check CI's competition here
OSCR vs CVS Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, CVS has a market cap of 74.3B. Regarding current trading prices, OSCR is priced at $14.20, while CVS trades at $58.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas CVS's P/E ratio is 14.02. In terms of profitability, OSCR's ROE is +0.11%, compared to CVS's ROE of +0.07%. Regarding short-term risk, OSCR is more volatile compared to CVS. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check CVS's competition here
OSCR vs ELV Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, ELV has a market cap of 63.1B. Regarding current trading prices, OSCR is priced at $14.20, while ELV trades at $280.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas ELV's P/E ratio is 11.89. In terms of profitability, OSCR's ROE is +0.11%, compared to ELV's ROE of +0.13%. Regarding short-term risk, OSCR is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check ELV's competition here
OSCR vs HUM Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, HUM has a market cap of 27.7B. Regarding current trading prices, OSCR is priced at $14.20, while HUM trades at $229.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas HUM's P/E ratio is 16.17. In terms of profitability, OSCR's ROE is +0.11%, compared to HUM's ROE of +0.10%. Regarding short-term risk, OSCR is more volatile compared to HUM. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check HUM's competition here
OSCR vs CNC Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, CNC has a market cap of 13.3B. Regarding current trading prices, OSCR is priced at $14.20, while CNC trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas CNC's P/E ratio is 3.95. In terms of profitability, OSCR's ROE is +0.11%, compared to CNC's ROE of +0.13%. Regarding short-term risk, OSCR is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check CNC's competition here
OSCR vs MOH Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, MOH has a market cap of 8.6B. Regarding current trading prices, OSCR is priced at $14.20, while MOH trades at $158.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas MOH's P/E ratio is 7.81. In terms of profitability, OSCR's ROE is +0.11%, compared to MOH's ROE of +0.25%. Regarding short-term risk, OSCR is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for OSCR.Check MOH's competition here
OSCR vs ALHC Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, ALHC has a market cap of 2.3B. Regarding current trading prices, OSCR is priced at $14.20, while ALHC trades at $11.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas ALHC's P/E ratio is -24.77. In terms of profitability, OSCR's ROE is +0.11%, compared to ALHC's ROE of -0.81%. Regarding short-term risk, OSCR is more volatile compared to ALHC. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check ALHC's competition here
OSCR vs CLOV Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, CLOV has a market cap of 1.6B. Regarding current trading prices, OSCR is priced at $14.20, while CLOV trades at $3.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas CLOV's P/E ratio is -76.87. In terms of profitability, OSCR's ROE is +0.11%, compared to CLOV's ROE of -0.07%. Regarding short-term risk, OSCR is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for OSCR.Check CLOV's competition here
OSCR vs BHG Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, OSCR is priced at $14.20, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas BHG's P/E ratio is -0.12. In terms of profitability, OSCR's ROE is +0.11%, compared to BHG's ROE of -0.47%. Regarding short-term risk, OSCR is more volatile compared to BHG. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check BHG's competition here
OSCR vs BMGL Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, BMGL has a market cap of 42.5M. Regarding current trading prices, OSCR is priced at $14.20, while BMGL trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas BMGL's P/E ratio is 226.00. In terms of profitability, OSCR's ROE is +0.11%, compared to BMGL's ROE of +0.32%. Regarding short-term risk, OSCR is more volatile compared to BMGL. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check BMGL's competition here
OSCR vs MRAI Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, MRAI has a market cap of 20M. Regarding current trading prices, OSCR is priced at $14.20, while MRAI trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas MRAI's P/E ratio is -0.46. In terms of profitability, OSCR's ROE is +0.11%, compared to MRAI's ROE of +0.75%. Regarding short-term risk, OSCR is more volatile compared to MRAI. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check MRAI's competition here
OSCR vs IVF Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, IVF has a market cap of 4.7M. Regarding current trading prices, OSCR is priced at $14.20, while IVF trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas IVF's P/E ratio is -0.02. In terms of profitability, OSCR's ROE is +0.11%, compared to IVF's ROE of -5.72%. Regarding short-term risk, OSCR is less volatile compared to IVF. This indicates potentially lower risk in terms of short-term price fluctuations for OSCR.Check IVF's competition here
OSCR vs NIVF Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, NIVF has a market cap of 2.4M. Regarding current trading prices, OSCR is priced at $14.20, while NIVF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas NIVF's P/E ratio is N/A. In terms of profitability, OSCR's ROE is +0.11%, compared to NIVF's ROE of +0.03%. Regarding short-term risk, OSCR is more volatile compared to NIVF. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check NIVF's competition here
OSCR vs MGLN Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, OSCR is priced at $14.20, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas MGLN's P/E ratio is 8.49. In terms of profitability, OSCR's ROE is +0.11%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, OSCR is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check MGLN's competition here
OSCR vs GTS Comparison July 2025
OSCR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OSCR stands at 3.6B. In comparison, GTS has a market cap of 0. Regarding current trading prices, OSCR is priced at $14.20, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OSCR currently has a P/E ratio of 35.50, whereas GTS's P/E ratio is 10.41. In terms of profitability, OSCR's ROE is +0.11%, compared to GTS's ROE of +0.07%. Regarding short-term risk, OSCR is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for OSCR.Check GTS's competition here